EUVIMEDEUVIMED entdecken
Crossref

Association of GLP1 ‐Receptor Agonists With Diabetic Retinopathy

Arisa Gonzalez, Lisa Chastain, Olga Karasik, Abdo Asmar, Monika Farhangi, Carlos A Alvarez iD, Ishak A Mansi iD

Diabetes, Obesity and Metabolism · 2026-11 · 28 (11) · 10586-10602

DOI: 10.1111/dom.71267 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetes, Obesity and Metabolism, online erschienen am 27.08.2026. Verfasst von Arisa Gonzalez und 6 weiteren Autor:innen. Beteiligte Einrichtung: University of Central Florida HCA Florida Healthcare, Orlando, Florida, USA. Hauptthemen laut MEDLINE: Diabetic Retinopathy, Glucagon-Like Peptide-1 Receptor Agonists, Diabetes Mellitus, Type 2, Hypoglycemic Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 49 Literaturangaben. Gefördert von: Orlando VA Healthcare System, NCATS NIH HHS, HCA Healthcare.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

We aimed to examine the association between glucagon‐like peptide‐1 receptor agonists (GLP1‐RA) use and diabetic retinopathy and non‐arteritic anterior ischemic optic neuropathy (NAION), using dipeptidyl peptidase‐4 inhibitors (DPP4i) as active comparators.

Methods

We created a retrospective propensity score (PS)‐matched cohort study of patients who initiated either GLP1‐RA or DPP4i (years 2006–2021). Using new‐users, we created two PS‐matched cohorts: patients with diabetes (overall cohort) and patients with diabetes and chronic kidney disease (CKD‐cohort); the latter represents patients at higher likelihood of diabetes microvascular complications. Primary outcomes were non‐vision‐threatening diabetic retinopathy (NVTDR), vision‐threatening diabetic retinopathy and diabetic macular edema (VTDR/DME), and NAION. Secondary outcomes included vision impairment or blindness and occurrence of retinopathy procedures.

Results

PS‐matched overall cohort included 98 082 pairs of GLP1‐RA or DPP4i users. GLP1‐RA users had higher risk of NVTDR (11.05% vs. 9.98%; odds ratio [OR] 1.12, 95% confidence interval [95% CI]: 1.09–1.15), VTDR/DME (2.17% vs. 1.98%; OR 1.09, 95% CI: 1.03–1.16), and occurrence of retinopathy procedures (4.16% vs. 3.68%, OR 1.14, 95% CI: 1.09–1.19). There was no significant difference in risk of NAION (OR 1.11, 95% CI: 0.96–1.29) or vision impairment or blindness (OR 1.04, 95% CI: 0.97–1.11). In the CKD cohort (15 440 matched pairs), GLP1‐RA was associated with high risk of NVTDR (OR 1.10, 95% CI: 1.03–1.18), and occurrence of retinopathy procedures (OR 1.14, 95% CI: 1.03–1.26), but not other outcomes.

Conclusions

GLP1‐RA use was associated with a modest increase in risk of diabetic retinopathy and retinopathy‐related procedures, independent of the presence of retinopathy at baseline. However, GLP1‐RA use was not associated with vision impairment or blindness, although administrative codes notably have low validity for blindness diagnosis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetic RetinopathyGlucagon-Like Peptide-1 Receptor AgonistsDiabetes Mellitus, Type 2Hypoglycemic AgentsHumansFemaleMaleRetrospective StudiesMiddle AgedAgedDipeptidyl-Peptidase IV InhibitorsPropensity Score

Stichwörter der Autor:innen

DPP‐IV inhibitorGLP‐1 analogueantidiabetic drugcohort studydatabase researchdiabetic retinopathy

Substanzen

Glucagon-Like Peptide-1 Receptor AgonistsDipeptidyl-Peptidase IV InhibitorsHypoglycemic Agents

Autor:innen und Institutionen

  • University of Central Florida HCA Florida Healthcare, Orlando, Florida, USA.
  • Department of Medicine, University of Central Florida, College of Medicine, Orlando, Florida, USA.
  • Department of Pharmacy Practice, Division of Ambulatory Care, Texas Tech University Health Sciences Center, Dallas, Texas, USA.
  • Clinical Pharmacy Services, VA North Texas Healthcare System - Fort Worth Outpatient Clinic, Fort Worth, Texas, USA.
  • Education Services, Orlando VA Healthcare System, Orlando, Florida, USA.
  • Department of Pharmacy Practice and Center for Excellence in Real World Evidence, Texas Tech University Health Sciences Center, Dallas, Texas, USA.

ORCID-Profile: Carlos A Alvarez, Ishak A Mansi

Förderung

  • Orlando VA Healthcare System
  • NCATS NIH HHS
  • HCA Healthcare
  • National Center for Advancing Translational Sciences

Zitieren

APA

Gonzalez, A., Chastain, L., Karasik, O., Asmar, A., Farhangi, M., Alvarez, C. A., & Mansi, I. A. (2026). Association of GLP1 ‐Receptor Agonists With Diabetic Retinopathy. Diabetes, Obesity and Metabolism, 28(11), 10586-10602. https://doi.org/10.1111/dom.71267

Vancouver

Gonzalez A, Chastain L, Karasik O, Asmar A, Farhangi M, Alvarez CA, et al. Association of GLP1 ‐Receptor Agonists With Diabetic Retinopathy. Diabetes, Obesity and Metabolism. 2026;28(11):10586-10602. doi:10.1111/dom.71267

BibTeX
@article{Gonzalez2026,
  author = {Gonzalez, Arisa and Chastain, Lisa and Karasik, Olga and Asmar, Abdo and Farhangi, Monika and Alvarez, Carlos A and Mansi, Ishak A},
  title = {Association of GLP1 ‐Receptor Agonists With Diabetic Retinopathy},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2026},
  volume = {28},
  number = {11},
  pages = {10586--10602},
  doi = {10.1111/dom.71267}
}
Kostenlos starten →